Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer

by Bakir Mehić, Mirko Stanetić, Ljuljeta Tinjić, Vlatka Smoljanović
Published 2008-11-01

Correlation of demographic, histological and molecular characteristics and clinical course of the disease in patients with lung adenocarcinoma

by Lora Novaković Lacković, Ljilja Latinović Tadić, Mirko Stanetić, Nataša Tanasković, Slavica Marić, Marko Lacković
Published 2019-08-01